Compare · AMGN vs MAZE
AMGN vs MAZE
Side-by-side comparison of Amgen Inc. (AMGN) and Maze Therapeutics Inc. (MAZE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and MAZE operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $182.28B, about 139.2x MAZE ($1.31B).
- Over the past year, AMGN is up 15.7% and MAZE is up 85.0% - MAZE leads by 69.3 points.
- AMGN has been more active in the news (19 items in the past 4 weeks vs 16 for MAZE).
- AMGN has more recent analyst coverage (25 ratings vs 7 for MAZE).
- Company
- Amgen Inc.
- Maze Therapeutics Inc.
- Price
- $337.73-2.00%
- $23.67-1.02%
- Market cap
- $182.28B
- $1.31B
- 1M return
- +2.51%
- -7.18%
- 1Y return
- +15.73%
- +84.99%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2025
- News (4w)
- 19
- 16
- Recent ratings
- 25
- 7
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest MAZE
- SEC Form 4 filed by Director Spiegelman Daniel K
- SEC Form 4 filed by Director Scheller Richard H
- SEC Form 4 filed by Director Lim Jonathan E
- SEC Form 4 filed by Director Hoppenot Herve
- SEC Form 4 filed by Director Homcy Charles J
- SEC Form 4 filed by Director Andrews Nancy C
- SEC Form 8-K filed by Maze Therapeutics Inc.
- Chief Executive Officer Coloma Jason V sold $174,048 worth of shares (6,643 units at $26.20) as part of a pre-agreed trading plan (SEC Form 4)
- President, R&D & CMO Bernstein Harold sold $381,112 worth of shares (14,853 units at $25.66) as part of a pre-agreed trading plan and exercised 14,853 shares at a strike of $10.42 (SEC Form 4)
- CSBO Dandekar Atul exercised 7,500 shares at a strike of $10.42 and sold $197,554 worth of shares (7,500 units at $26.34) as part of a pre-agreed trading plan (SEC Form 4)